Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Peter C TaylorGeorg SchettThomas Wj HuizingaQingmin WangFowzia IbrahimBei ZhouSophia G LivaJafar Sadik B ShaikYuan XiongJocelyn H LeuRohit A PanchakshariMatthew J LozaKeying MaHarman DhattRicardo Rojo CellaChetan S KaryekarCarolyn A CuffSheng GaoKaiyin Fei

Published in: RMD open (2024)

NCT04991753.

Keyphrases

rheumatoid arthritis
monoclonal antibody
disease activity
ankylosing spondylitis
interstitial lung disease
early onset
stem cells
cell therapy
drug induced
idiopathic pulmonary fibrosis
smoking cessation